Literature DB >> 3315578

Physiological balance of haemostasis and bleeding.

V J Marder1, C W Francis.   

Abstract

A complex series of cellular and molecular interactions is involved in fibrinolysis, which is controlled by mechanisms that provide for localised activation or suppression without systemic effects, thereby providing an orderly process of haemostasis, healing and response to thrombotic injury. Excessive or deficient fibrinolysis may be congenital or acquired, the latter including iatrogenic interventions, and such variations in the balance may result in accelerated recovery from disease or a thrombotic or haemorrhagic complication.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3315578     DOI: 10.2165/00003495-198700333-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  20 in total

1.  A plasminogen activator in spontaneously active human blood.

Authors:  S MULLERTZ
Journal:  Proc Soc Exp Biol Med       Date:  1953-02

2.  Pro-urokinase: a study of its stability in plasma and of a mechanism for its selective fibrinolytic effect.

Authors:  R Pannell; V Gurewich
Journal:  Blood       Date:  1986-05       Impact factor: 22.113

3.  Common evolutionary origin of the fibrin-binding structures of fibronectin and tissue-type plasminogen activator.

Authors:  L Bányai; A Váradi; L Patthy
Journal:  FEBS Lett       Date:  1983-10-31       Impact factor: 4.124

4.  The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings.

Authors: 
Journal:  N Engl J Med       Date:  1985-04-04       Impact factor: 91.245

5.  Abnormal plasminogen. A hereditary molecular abnormality found in a patient with recurrent thrombosis.

Authors:  N Aoki; M Moroi; Y Sakata; N Yoshida; M Matsuda
Journal:  J Clin Invest       Date:  1978-05       Impact factor: 14.808

6.  Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI).

Authors: 
Journal:  Lancet       Date:  1986-02-22       Impact factor: 79.321

7.  Quantitative venographic assessment of deep vein thrombosis in the evaluation of streptokinase and heparin therapy.

Authors:  V J Marder; R L Soulen; V Atichartakarn; A Z Budzynski; S Parulekar; J R Kim; N Edward; J Zahavi; K M Algazy
Journal:  J Lab Clin Med       Date:  1977-05

8.  Human endothelial cells produce a plasminogen activator inhibitor and a tissue-type plasminogen activator-inhibitor complex.

Authors:  M Philips; A G Juul; S Thorsen
Journal:  Biochim Biophys Acta       Date:  1984-11-06

9.  Rapid lysis of coronary artery thrombi with anisoylated plasminogen: streptokinase activator complex. Treatment by bolus intravenous injection.

Authors:  V J Marder; R L Rothbard; P G Fitzpatrick; C W Francis
Journal:  Ann Intern Med       Date:  1986-03       Impact factor: 25.391

10.  Fibrinolysis with acyl-enzymes: a new approach to thrombolytic therapy.

Authors:  R A Smith; R J Dupe; P D English; J Green
Journal:  Nature       Date:  1981-04-09       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.